1. Kinetics of the Humoral Antibody Response

Humoral immunity is mediated by serum antibodies secreted by differentiated B cells. The activation, proliferation, and differentiation of naive B cells into antibody-secreting plasma cells and long-lived memory cells show distinct kinetic phases depending on whether the host is encountering an immunogen for the first or subsequent times.

Figure: Primary vs. Secondary Humoral Antibody Response. The primary response to a first antigen exposure shows a long lag phase (5–10 days), a modest exponential rise dominated by IgM, and a comparatively brief plateau before decline. Memory B and T cells generated during this response allow a second exposure to the same antigen to trigger a secondary (anamnestic) response with a near-negligible lag (1–3 days), a much steeper rise, a peak titer several log-folds higher, and a prolonged plateau dominated by IgG.

1.1 The Primary Humoral Response

The primary immunisation represents the host's first exposure to a specific immunogen. The resulting primary response is divided into four chronological phases:

• Phase 1
  Lag (Latent) Phase

  The initial window following antigen exposure during which no specific antibodies are detectable in the serum. This phase is characterized by antigen localization, helper T-cell activation, B-cell clonal selection, and early proliferation. It typically lasts 5 to 10 days (though it can extend to 1–2 weeks depending on the immunogen and route of entry).

• Phase 2
  Log (Exponential) Phase

  Active antibody secretion begins. The serum antibody titer rises exponentially as B cells differentiate into active plasma cells.

• Phase 3
  Plateau (Steady State) Phase

  A kinetic equilibrium is reached where the rate of antibody synthesis balances the rate of antibody clearance and degradation.

• Phase 4
  Decline Phase

  The concentration of circulating antibodies decreases rapidly as the antigen is cleared and short-lived plasma cells undergo apoptosis.

1.2 The Secondary (Anamnestic) Humoral Response

A subsequent encounter with the same immunogen triggers a secondary response. This is driven by antigen-specific memory B and T cells established during the primary response. It differs both quantitatively and qualitatively from the primary response:

• Feature 1
  Negligible Lag Phase

  The latent period is dramatically reduced to 1 to 3 days.

• Feature 2
  Rapid and Massive Log Phase

  The antibody titer rises far more steeply, reaching peak levels that are several log-folds higher than in the primary response.

• Feature 3
  Prolonged Plateau Phase

  High antibody concentrations persist in the serum for much longer periods.

• Feature 4
  Gradual Decline

  Antibody levels subside slowly over months or years.

1.3 Quantitative and Qualitative Comparison of Humoral Responses

1.4 Molecular Drivers of Qualitative Shifts

2. Antibody-Mediated Effector Functions

Antibodies act as molecular adapters. Their amino-terminal variable domains (V_H/V_L) bind specific foreign antigens, while their carboxyl-terminal constant domains (C_H) interact with Fc receptors (FcR) on effector cells or engage the complement cascade.

Figure: Basic Immunoglobulin Structure. Each antibody monomer is built from paired heavy and light chains. The amino-terminal tips of the two Fab arms form the variable region (V_H/V_L), which determines antigen specificity, while the constant region of the Fab arms (C_H1/C_L) and the flexible hinge connect to the Fc stem (C_H2/C_H3). The Fc stem is the docking site for Fc receptors on effector cells and for the complement recognition subunit C1q.

The five major in vivo effector mechanisms of antibodies are:

2.1 Neutralisation

Antibodies bind to the surface epitopes of viruses, bacteria, or extracellular toxins, physically blocking their interaction with host cell receptors.

• Detail 1
  Pathogen Neutralisation

  Prevents viral entry (fusion or endocytosis) and blocks bacterial attachment to mucosal surfaces.

• Detail 2
  Toxin Neutralisation

  Blocks the binding of toxins (e.g., diphtheria, tetanus, or shiga toxins) to target receptors on host cells, preventing pathology.

• Detail 3
  Primary Isotypes

  Systemic neutralisation is mediated primarily by IgG, while mucosal neutralisation is dominated by secretory dimer IgA.

2.2 Opsonisation

Phagocytic cells, such as macrophages and neutrophils, express surface Fc receptors (FcR) that bind to the Fc portion of antibodies coating a pathogen.

• Detail 1
  Mechanism

  Unbound monomeric IgG has low affinity for Fc receptors, preventing non-specific activation. However, when multiple IgG molecules bind to repetitive epitopes on a pathogen's surface, they cluster. This multivalent arrangement allows high-avidity binding to surface Fcγ receptors (FcγR) on the phagocyte, triggering membrane pseudopodia formation, engulfment (phagocytosis), and lysosomal fusion.

• Detail 2
  Primary Isotypes

  In humans, IgG1 and IgG3 are the most efficient opsonins.

2.3 Classical Complement Activation

Complement is a system of circulating inactive serum proteins that undergo sequential enzymatic cleavage upon activation.

• Detail 1
  Mechanism

  Antigen-antibody complex formation exposes a binding site in the C_H2 domain of IgG or the C_H3 domain of IgM. This allows the binding of C1q, the recognition subunit of the C1 complex.

• Detail 2
  Structural Constraint

  C1q must bind to at least two Fc constant regions simultaneously to initiate activation. Because IgM is a pentamer, a single bound IgM molecule can easily recruit and activate the classical complement cascade. In contrast, multiple IgG molecules must bind in close proximity on a membrane surface to allow C1q to bridge them.

• Detail 3
  Primary Isotypes

  IgM is the most potent activator, followed by IgG1, IgG3, and IgG2.

2.4 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

ADCC bridges humoral and cellular immunity, allowing the destruction of large, antibody-coated target cells (such as virus-infected or tumor cells) that cannot be phagocytosed.

• Detail 1
  Mechanism

  Effector cells, primarily Natural Killer (NK) cells, express the low-affinity Fc receptor FcγRIII (CD16). When target host cells express foreign viral or tumor antigens on their membranes, IgG antibodies bind to these antigens. NK cells then bind the clustered Fc regions via CD16.

• Detail 2
  Lytic Output

  Cross-linking CD16 activates the NK cell, triggering degranulation and the directional release of perforin and granzymes, which induce apoptosis in the target cell.

• Detail 3
  Primary Isotypes

  Mediated by IgG1 and IgG3 subclasses.

2.5 Mast Cell and Eosinophil Activation

• Detail 1
  Mast Cell Degranulation

  IgE molecules bind with high affinity to FcεRI receptors on mast cells and basophils. Subsequent antigen cross-linking of these bound IgE molecules triggers immediate degranulation, releasing vasoactive amines (histamine, serotonin) to initiate allergic and immediate hypersensitivity reactions.

• Detail 2
  Eosinophil-Mediated Helminthic Lysis

  Large parasites (such as helminthic worms) are too large for phagocytosis. IgE coats the parasite, and eosinophils bind these IgE molecules via Fcε receptors. This triggers the extracellular release of highly toxic cationic granule proteins and reactive oxygen species (ROS) to damage the parasite's tegument.

3. Monoclonal Antibodies and Hybridoma Technology

In nature, exposure to an immunogen yields a polyclonal antiserum containing antibodies secreted by multiple B-cell clones, each recognising a different epitope. In 1975, Georges Köhler and César Milstein developed hybridoma technology to generate monoclonal antibodies (mAbs)—monospecific antibodies produced by a single clone of B cells directed against a single epitope.

3.1 Biochemical Principles of HAT Selection

Normal somatic cells do not survive indefinitely in vitro, whereas cancerous myeloma cells are immortal but lack the ability to secrete specific antibodies. Hybridoma technology fuses primary antibody-producing B cells (from the spleen of an immunised mouse) with immortalised myeloma cells using polyethylene glycol (PEG).

Selecting successfully fused hybridomas from unfused cells and non-productive fusions relies on a selective growth medium called HAT (Hypoxanthine-Aminopterin-Thymidine) medium:

Figure: Nucleotide Biosynthesis Pathways in HAT Selection. Under normal conditions, cells build nucleotides via the de novo pathway from simple precursors. Aminopterin blocks this route by inhibiting dihydrofolate reductase (DHFR). Survival in HAT medium then depends entirely on the salvage pathway, which recycles exogenous hypoxanthine and thymidine into nucleotides — but only in cells with functional HGPRT and TK enzymes.

• Step 1
  De Novo Pathway Blockade

  Under normal culture conditions, cells synthesise purine and pyrimidine nucleotides using simple precursors through the de novo pathway. Aminopterin acts as a competitive inhibitor of dihydrofolate reductase (DHFR), blocking the reduction of dihydrofolate to tetrahydrofolate. This completely shuts down the de novo synthesis of purines and thymidylate.

• Step 2
  Salvage Pathway Dependency

  To survive in the presence of aminopterin, cells must utilise the alternative salvage pathway. This pathway recycles preformed purines and pyrimidines using exogenous hypoxanthine and thymidine. Utilizing the salvage pathway requires two functional enzymes:

  • HGPRT (Hypoxanthine-Guanine Phosphoribosyl Transferase) to process hypoxanthine.
  • TK (Thymidine Kinase) to process thymidine.
• Step 3
  The Selection Mechanism
  • Myeloma Cells: The parental myeloma line is genetically selected to be deficient in HGPRT (HGPRT⁻). Consequently, they cannot utilise the salvage pathway. In HAT medium, their de novo pathway is blocked by aminopterin, and they cannot salvage hypoxanthine due to the HGPRT deficiency. Unfused myeloma cells and homotypic myeloma-myeloma fusions thus die in HAT medium.
  • Unfused Spleen Cells: Although spleen B cells are genetically normal (HGPRT⁺) and can use the salvage pathway, they are primary somatic cells with a short lifespan in culture. Unfused spleen cells and homotypic spleen-spleen fusions die naturally within a few days.
  • Hybridoma Cells: Heterotypic spleen-myeloma fusions inherit immortality from the myeloma parent and a functional HGPRT gene from the splenic B-cell parent. These cells survive HAT selection, multiply, and are screened for the secretion of the desired antibody.

3.2 Recombinant Antibody Engineering

Therapeutic application of murine mAbs in humans is limited by their immunogenicity; the human immune system recognizes mouse antibodies as foreign, generating Human Anti-Mouse Antibodies (HAMA) that clear the therapy. Recombinant DNA technology has enabled the engineering of safer, less immunogenic variants:

• Type 1
  Chimeric Antibodies

  Constructed by fusing the variable domains (V_H and V_L, containing the antigen-binding sites) of a murine antibody with the constant domains (C_H and C_L) of a human antibody. The resulting antibody is approximately 65% human.

• Type 2
  Humanised Antibodies

  Produced by grafting only the hypervariable loops—the Complementarity-Determining Regions (CDRs)—of the murine antibody onto human variable region frameworks (FR_H and FR_L), which are then joined to human constant regions. The resulting antibody is approximately 95% human.

• Type 3
  Immunotoxins

  Recombinant protein therapeutics containing a target-specific antigen-binding domain (typically a monoclonal antibody or single-chain variable fragment, scFv) conjugated to a potent cytotoxic domain (such as plant or bacterial toxins: ricin, abrin, shiga toxin, or diphtheria toxin). Once the antibody binds its target cell-surface antigen, the immunotoxin is endocytosed, and the toxin domain translocates to the cytosol, where it inhibits ribosomal protein synthesis to kill the target cell.

• Type 4
  Heteroconjugates / Bispecific Antibodies

  Artificial hybrid molecules constructed by chemically or genetically cross-linking two different antibody binding sites. These do not occur in nature. One binding site is typically directed against a tumor-associated antigen, while the other is specific for a surface molecule on an immune effector cell (such as CD3 on T cells or CD16 on NK cells). This physical cross-linking bypasses normal MHC recognition, bringing immune effector cells into close proximity with tumor cells to drive target-cell destruction.

4. The T-Cell Receptor (TCR) Complex and Accessory Molecules

Unlike B cells, which recognize native soluble antigens, T cells recognize processed peptide fragments bound to Major Histocompatibility Complex (MHC) molecules on the surface of Antigen-Presenting Cells (APCs).

4.1 TCR Structural Biology

The TCR is a membrane-bound monovalent heterodimer. It is never secreted.

• Isoform 1
  αβ TCR

  Expressed by over 90% of peripheral T cells. Composed of an α chain and a β chain linked by an interchain disulfide bond.

• Isoform 2
  γδ TCR

  Expressed by less than 10% of T cells, primarily enriched in epithelial environments (skin, intestinal mucosa, lungs). These receptors display limited diversity and can recognize lipids, glycolipids, or phosphoantigens presented by non-classical MHC-like CD1 molecules without requiring antigen processing.

• Structure
  Domain Architecture

  Each chain of the heterodimer consists of:

  • An amino-terminal Variable (V) domain containing three hypervariable loops (CDRs) that form the antigen-binding site.
  • A Constant (C) domain containing an immunoglobulin-like fold.
  • A hinge-like region containing the cysteine residue that forms the interchain disulfide bond.
  • A hydrophobic transmembrane region containing positively charged (basic) amino acid residues (lysine, arginine) that interact with the negatively charged residues in the transmembrane domains of the CD3 complex.
  • A very short cytoplasmic tail.

4.2 The CD3 Signaling Apparatus

The TCR heterodimer lacks intrinsic signaling capability due to its short cytoplasmic tails. Signaling requires association with the CD3 complex, a highly conserved, invariant octameric signaling apparatus.

Figure: The TCR-CD3 Signaling Complex. The TCR αβ heterodimer itself has no signaling capacity — it associates non-covalently with the CD3 complex, made up of CD3γε and CD3δε heterodimers flanking a central CD3ζζ homodimer. Each CD3γ, δ, and ε chain carries a single ITAM, while each CD3ζ chain carries three, making the ζζ homodimer the dominant contributor to downstream signal amplification.

• Composition
  Subunit Composition

  The CD3 complex is composed of three dimers:

  • A CD3γε heterodimer.
  • A CD3δε heterodimer.
  • A CD3ζζ homodimer (or occasionally a ζη heterodimer).
• Signaling
  ITAMs

  Immunoreceptor Tyrosine-based Activation Motifs. The cytoplasmic tails of the CD3 chains contain conserved ITAM sequences (YXXL/I-X_6-8-YXXL/I). These motifs serve as docking sites for intracellular protein tyrosine kinases following receptor ligation.

  • The CD3γ, δ, and ε chains each contain a single ITAM.
  • The CD3ζ chains each contain three ITAMs.
  • The complete TCR-CD3 complex contains a total of ten ITAMs (one from each of the two γε/δε heterodimer chains and six from the ζζ homodimer), enabling signal amplification.

4.3 TCR Co-Receptors: CD4 and CD8

CD4 and CD8 act as physical co-receptors. They bind to conserved regions of the MHC molecule, stabilizing the TCR-MHC interaction and recruiting intracellular signaling molecules.

5. Thymic Ontogeny and Selection Checkpoints

T-cell precursors migrate from the bone marrow via the bloodstream to the thymus, where they mature, rearrange their TCR genes, and undergo selection to ensure self-tolerance and MHC restriction.

5.1 Double-Negative (DN) Checkpoints

Precursors arriving in the thymus lack expression of CD4, CD8, and mature TCRs. This early phase is known as the double-negative (DN) stage and is divided into four distinct developmental steps:

Figure: Double-Negative Thymocyte Development. Precursors progress through DN1–DN3 in the thymic cortex while rearranging the TCRβ locus. Successful pre-TCR assembly at DN3 triggers proliferation and drives the transition through DN4 into the Double-Positive (DP) stage, where CD4 and CD8 are both upregulated.

• Checkpoint 1
  DN1 Stage (c-Kit⁺⁺, CD44⁺, CD25⁻)

  Precursors enter the corticomedullary junction of the thymus. TCR genes remain in their unrearranged, germline configuration.

• Checkpoint 2
  DN2 Stage (c-Kit⁺⁺, CD44⁺, CD25⁺)

  Thymocytes migrate to the cortex. Rearrangement of the TCR β, γ, and δ loci begins. Cells commit to the T-cell lineage.

• Checkpoint 3
  DN3 Stage (c-Kit⁺, CD44⁻, CD25⁺)

  Proliferation halts as cells complete rearrangement of the TCR β chain.

  • The pre-TCR Checkpoint: The newly rearranged β chain pairs with an invariant surrogate pre-Tα chain to form the pre-TCR. The pre-TCR non-covalently associates with the CD3 complex. Successful assembly of the pre-TCR sends a signal to the cell nucleus that:
    • Stops further rearrangement of the β chain locus (allelic exclusion).
    • Initiates several rounds of rapid proliferation.
    • Drives transition into the DN4 stage.
• Checkpoint 4
  DN4 Stage (c-Kit low/⁻, CD44⁻, CD25⁻)

  Proliferating cells downregulate CD25 and transition to the Double-Positive (DP) stage.

5.2 Double-Positive (DP) Stage and Thymic Selection

Upon completing the DN4 stage, thymocytes upregulate both CD4 and CD8 to become Double-Positive (CD4⁺CD8⁺) thymocytes. During this stage, rearrangement of the TCR α chain locus begins, replacing the pre-Tα surrogate chain with a mature α chain to produce a fully formed αβ TCR. These DP thymocytes must pass two screening processes:

Figure: Thymic Selection of Double-Positive Thymocytes. Every DP thymocyte is screened against self-MHC-peptide complexes on thymic epithelial cells. No binding leads to death by neglect (~95% of cells); low-to-moderate affinity binding triggers positive selection and lineage commitment to a CD4⁺ or CD8⁺ single-positive (SP) cell; high-affinity binding to self-peptide triggers negative selection and deletion to enforce self-tolerance.

• Screen 1
  Positive Selection (MHC Restriction)
  • Location & Mediators: Occurs in the thymic cortex, mediated by cortical thymic epithelial cells (cTECs) expressing both MHC Class I and MHC Class II molecules.
  • Mechanism: DP thymocytes probe the cTECs' MHC-peptide complexes. Thymocytes whose TCRs bind to MHC-peptide complexes with low-to-moderate affinity receive a survival signal.
  • Death by Neglect: Thymocytes whose TCRs cannot bind MHC-peptide complexes fail to receive survival signals. Approximately 95% of DP thymocytes die via default apoptosis (death by neglect), ensuring the surviving population is restricted to recognizing self-MHC.
  • Lineage Commitment: Survival triggers the transition of the DP thymocyte into a Single-Positive (SP) thymocyte:
    • If the TCR binds preferentially to MHC Class II, the cell downregulates CD8, becoming a CD4⁺ T cell.
    • If the TCR binds preferentially to MHC Class I, the cell downregulates CD4, becoming a CD8⁺ T cell.
• Screen 2
  Negative Selection (Self-Tolerance)
  • Location & Mediators: Occurs primarily at the corticomedullary junction and medulla, mediated by medullary thymic epithelial cells (mTECs), dendritic cells, and macrophages.
  • Mechanism: Cells are exposed to self-antigens. Thymocytes whose TCRs bind self-MHC-peptide complexes with high affinity are deleted via apoptosis. This process eliminates highly autoreactive T cells, preventing autoimmune pathology.

6. T-Cell Activation and Differentiation

Naive Single-Positive T cells exit the thymus and enter the blood and secondary lymphoid organs. Activating these cells to drive clonal expansion and differentiation requires three distinct signals delivered by an Antigen-Presenting Cell (APC).

Figure: The Three-Signal Model of T-Cell Activation. The APC presents MHC-II and B7 co-stimulatory ligands, which engage TCR-CD3 (Signal 1) and CD28 (Signal 2) on the naive T cell. Local cytokines then deliver Signal 3, steering the activated T cell toward a specific functional differentiation program.

6.1 The Three-Signal Hypothesis

• Signal 1
  Antigen Recognition

  The TCR-CD3 complex binds to the MHC-peptide complex on the APC, and the CD4 or CD8 co-receptor binds to a conserved domain on the MHC molecule. This drives downstream Lck activation.

• Signal 2
  Co-stimulation

  The costimulatory receptor CD28 on the T-cell membrane binds to B7-1 (CD80) or B7-2 (CD86) ligands on the APC.

  • Physiological Consequence: Signal 1 without Signal 2 induces anergy (a state of permanent non-responsiveness) or apoptosis. Signal 2 enhances cell survival, drives IL-2 transcription, and stabilizes cytokine mRNAs.
• Signal 3
  Cytokine Signaling

  The APC secretes local polarizing cytokines that bind to specific cytokine receptors on the activated T cell. Signal 3 determines the functional differentiation pathway of the T cell.

6.2 CD4⁺ T-Helper (T_H) Subset Differentiation

Under the influence of polarizing cytokines (Signal 3), activated naive CD4⁺ T cells (T_H0) differentiate into distinct functional subsets, each characterised by a unique profile of effector cytokines:

6.3 Cross-Regulation Between Subsets

To prevent inappropriate immune responses, T_H1 and T_H2 subsets actively suppress each other's development:

• Cross-Reg 1
  IFN-γ (from T_H1)

  IFN-γ secreted by active T_H1 cells acts back on naive T cells to promote T_H1 development while directly inhibiting T_H2 proliferation.

• Cross-Reg 2
  IL-4 (from T_H2)

  IL-4 secreted by active T_H2 cells acts back on naive T cells to promote T_H2 development while inhibiting IL-12 secretion by APCs, blocking the differentiation of naive T cells into T_H1 cells.

7. Cytotoxic T Lymphocyte (CTL) Effector Mechanisms

Naive CD8⁺ T cells are activated by MHC Class I-peptide complexes on licensed APCs, often with helper T_H1 cytokines (such as IL-2). Once activated, they differentiate into functional Cytotoxic T Lymphocytes (CTLs), which migrate throughout the body to eliminate virus-infected, intracellularly infected, or malignant host cells.

Figure: CTL Dual Killing Pathways. CTLs induce target-cell apoptosis through two independent routes: the granzyme-perforin pathway, where perforin pores allow granzyme B entry, and the Fas-FasL pathway, where receptor ligation triggers a caspase cascade. Both converge on the same endpoint — apoptotic DNA fragmentation into a characteristic 200 bp ladder.

7.1 The Granzyme-Perforin Pathway (Exocytosis of Granules)

This is the primary pathway used by CTLs to kill infected or aberrant cells. It is a Ca²⁺-dependent, energy-requiring process:

• Step 1
  Conjugate Formation

  The CTL's TCR-CD3 complex and CD8 co-receptor bind to the MHC Class I-peptide complex on the target cell. Adhesion molecules (such as LFA-1 on the CTL and ICAM-1 on the target cell) undergo conformational changes to form an immunological synapse, sealing the intercellular space.

• Step 2
  Granule Reorientation

  The CTL's centrosome and lytic granules migrate toward the site of contact.

• Step 3
  Perforin Action

  The granules undergo exocytosis, releasing their contents into the immunological synapse. Perforin molecules polymerize in the presence of Ca²⁺, inserting into the target cell membrane to form hydrophilic transmembrane pores.

• Step 4
  Granzyme B Entry

  Granzyme B (a serine protease) enters the target cell's cytoplasm, either through perforin pores or via receptor-mediated endocytosis. Once inside, Granzyme B initiates apoptosis through two mechanisms:

  • Caspase Activation: Directly cleaves and activates initiator Caspase-8 and effector Caspase-3.
  • Mitochondrial Damage: Cleaves Bid to its active form (tBid). tBid translocates to the mitochondria, triggering the release of cytochrome c into the cytosol, which activates the apoptosome and downstream caspases.
• Step 5
  Apoptotic DNA Fragmentation

  Downstream executioner caspases cleave inhibitor proteins to activate Caspase-Activated DNase (CAD). CAD cleaves genomic DNA at vulnerable linker regions between nucleosomes, yielding a characteristic ladder of 200 base pair (bp) oligomers.

7.2 The Fas-FasL Apoptotic Pathway

This pathway relies on receptor-ligand interactions on the cell surface and does not require granule exocytosis:

• Step 1
  Upregulation

  Upon activation, CTLs express high levels of Fas Ligand (FasL), a TNF family transmembrane protein, on their outer membranes.

• Step 2
  Ligation

  The CTL's FasL binds to Fas (CD95), a transmembrane death receptor expressed on the target cell.

• Step 3
  Death Domain Signalling

  Ligation triggers the trimerisation of Fas. The intracellular death domains of Fas recruit the adapter protein FADD (Fas-Associated Death Domain).

• Step 4
  Caspase Cascade

  FADD recruits and cleaves pro-caspase-8 to form active Caspase-8. Active Caspase-8 then directly cleaves and activates downstream effector caspases (such as Caspase-3), initiating the apoptotic cascade and destroying the target cell.